ENDRA Life Sciences Inc.
NDRA- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001681682
No open-market purchases or sales by ENDRA Life Sciences Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $819.0K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 10
- 13F valueReported value at the end of Q2 2026
- $819.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NDRA, Q2 2026
No superinvestor reported holding NDRA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by ENDRA Life Sciences Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 5, 2024 (view filing) | Aug 27 | 9 days | UBS Group AGOther: Market maker/broker-dealer | PPurchase | 0 | – | $0 | 0.0%146.0K after | Amended |
| May 22, 2023 (view filing) | May 18 | 4 days | Thornton Michael MilosChief Technology Officer | PPurchase | +15.0K | $1.65 | +$24.8K | +78.4%34.1K after | |
| May 3, 2023 (view filing)4:07 PM ET | May 2 | 1 day | Digiandomenico AnthonyDirector | PPurchase | +83.3K | $1.20 | +$100.0K | +436.3%102.4K after | |
| May 3, 2023 (view filing)4:07 PM ET | May 2 | 1 day | Digiandomenico AnthonyDirector | PPurchase | +41.7K | $0.01 | +$416.67 | –41.7K after | Derivative |
| Dec 13, 2022 (view filing) | Dec 9 | 4 days | Thornton Michael MilosChief Technology Officer | PPurchase | +1.50K | $3.40 | +$5.10K | +8.5%19.1K after | |
| Nov 28, 2022 (view filing)5:00 PM ET | Nov 23 | 5 days | Tokman Alexander YDirector | PPurchase | +10.0K | $0.17 | +$1.70K | +6.5%162.9K after | |
| Aug 24, 2022 (view filing)8:57 AM ET | Aug 22 | 2 days | Thornton Michael MilosChief Technology Officer | PPurchase | +20.0K | $0.27 | +$5.40K | +6.0%352.8K after | |
| Aug 24, 2022 (view filing)8:55 AM ET | Aug 22 | 2 days | Tokman Alexander YDirector | PPurchase | +20.0K | $0.26 | +$5.20K | +15.1%152.9K after | |
| May 31, 2022 (view filing)8:46 AM ET | May 26 | 5 days | Thornton Michael MilosChief Technology Officer | PPurchase | +25.0K | $0.21 | +$5.25K | +8.1%332.8K after | |
| May 23, 2022 (view filing)4:30 PM ET | May 18 | 5 daysLate | Thornton Michael MilosChief Technology Officer | PPurchase | +25.0K | $0.22 | +$5.50K | +8.8%307.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in ENDRA Life Sciences Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Altium Capital Management LP | 59,272 | $315.9K | 0.67% | +7,372+14.2% | Added |
| Citadel Advisors LLC | 29,924 | $159.5K | 0.00% | +29,924 | New |
| Citizens Financial Group Inc | 28,400 | $151.4K | 0.00% | +28,400 | New |
| Geode Capital Management, LLC | 14,910 | $79.5K | 0.00% | −6,168−29.3% | Reduced |
| Vanguard Fiduciary Trust Co | 10,121 | $53.9K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,339 | $39.1K | 0.00% | +4,523+160.6% | Added |
| Morgan Stanley | 3,546 | $18.9K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 68 | $362 | 0.00% | −84−55.3% | Reduced |
| Tower Research Capital LLC (TRC) | 58 | $309 | 0.00% | +58 | New |
| Northwestern Mutual Wealth Management Co | 19 | $101 | 0.00% | 00.0% | Unchanged |